– Interventional Radiologist, Tumor Embolization US
Future trends such as the immunotherapy used in combination with embolization technologies is gaining prominence. Expanded indications of embolization to treat cancer types such as prostate cancer and cholangiocarcinoma is expected to increase as clinical evidence suggests good patient outcomes.
Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such Fluidx Medical’s GPX embolic device’s repeated success in treating complex tumors including a recent case for renal tumor at Christchurch hospital in New Zealand; GPX embolic device being under development, not having marketing clearance or approval in any market at this time and being available for investigational use only in New Zealand are covered in the report.
We provide the best insights for your business